PRESS RELEASE
23 September 2020

Morrison & Foerster Advises Santen Pharmaceutical Co., Ltd In $225 Million Share Purchase Agreement With Eyevance Pharmaceuticals Holdings Inc.

MF
Morrison & Foerster LLP

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.
Morrison & Foerster advised Santen Pharmaceutical Co., Ltd., a company dedicated to ophthalmology, in its acquisition of Eyevance Pharmaceuticals Holdings Inc.,...
United States

Morrison & Foerster advised Santen Pharmaceutical Co., Ltd., a company dedicated to ophthalmology, in its acquisition of Eyevance Pharmaceuticals Holdings Inc., a company that develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment, through Santen's wholly owned U.S. subsidiary for $225 million.

The MoFo deal team is led by San Francisco corporate partner Jackie Liu, with additional support from corporate associates Michael G. Williams and James Lee, and technology transactions attorneys Masato Hayakawa and Chantelle Southerland.

Read Santen's press release about the transaction: Santen and U.S. Ophthalmic Company Eyevance Enters into Share Purchase Agreement.

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More